Postherpetic Neuralgia Pipeline Featuring 12+ Companies Expected to Change the Pace of the Postherpetic Neuralgia Treatment

"The neuralgia is excruciating with superimposed lancinating paresthesias. Pain may be constant or intermittent, aggravated by minor stimulus (allodynia) such as heat or touch, and is worse at night. The agony of pain leads to insomnia, anorexia, and changes in mood (severe depression)"

The drug is described in detail in the Postherpetic Neuralgia pipeline report, along with its mechanism of action, Postherpetic Neuralgia clinical trials, Postherpetic Neuralgia NDA approvals (if any), and product development activities that include technology, Postherpetic Neuralgia collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related information.

DelveInsight's "Postherpetic Neuralgia Pipeline Insight, 2023," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including Postherpetic Neuralgia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Postherpetic Neuralgia Pipeline Report

• The Postherpetic Neuralgia pipeline report from DelveInsight shows a healthy market with 12+ Companies actively working on 12+ pipeline therapies for the Postherpetic Neuralgia treatment.

• The leading Postherpetic Neuralgia Companies include Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.

• Promising Postherpetic Neuralgia Pipeline Therapies include Lidocaine 5% medicated plaster, Pregabalin, HSK16149 20mg BID, HSK16149 40mg BID, Lyrica (pregabalin), DS-5565, pregabalin, Fentanyl, Lidoderm, and others.

• The Postherpetic Neuralgia Companies and academics that are working to assess challenges and seek opportunities that could influence Postherpetic Neuralgia R&D. The Postherpetic Neuralgia pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

Request a sample and discover the recent advances in Postherpetic Neuralgia Drug Treatment @ Postherpetic Neuralgia Pipeline Report- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Overview
Post-herpetic neuralgia (PHN) is defined as a chronic neuropathic pain that persists for three or more months following acute Herpes zoster (shingles) infection. It is a severe painful secondary phase, which may develop three to six months after the resolution of initial phase of Herpes zoster (HZ) infection. Pain has a dermatomal distribution and is confined to same dermatome as the rash.

Recent Developmental Activities in the Postherpetic Neuralgia Treatment Landscape

• LX9211 and another development candidate were discovered by scientists working within Lexicon's drug discovery alliance with Bristol-Myers Squibb from which Lexicon hold exclusive development and commercialization rights. Currently, it is in Phase II stage of clinical trial evaluation to treat Postherpetic Neuralgia.

Find out more information of the latest Postherpetic Neuralgia Drugs Launch, News, and Breakthroughs of the Postherpetic Neuralgia Pipeline Report @ Latest Postherpetic Neuralgia Drugs Launch- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Emerging Drugs Profile

• HSK16149: Haisco Pharmaceutical Group
HSK16149 is being developed by Haisco Pharmaceutical Group to treat Postherpetic Neuralgia. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled, 12-week, Phase III study to evaluate the efficacy and safety of HSK16149 capsules in chinease patients with Postherpetic Neuralgia.

• LX9211: Lexicon Pharmaceuticals
LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain. Scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in a target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models.

Postherpetic Neuralgia Pipeline Therapeutics Assessment
There are approx. 12+ key companies which are developing the therapies for Postherpetic Neuralgia. The companies which have their Postherpetic Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Haisco Pharmaceutical Group.

Learn more about the emerging Postherpetic Neuralgia pipeline therapies @ Postherpetic Neuralgia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Postherpetic Neuralgia Pipeline Report

• Coverage- Global

• Postherpetic Neuralgia Companies- Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.

• Postherpetic Neuralgia Pipeline Therapies- Lidocaine 5% medicated plaster, Pregabalin, HSK16149 20mg BID, HSK16149 40mg BID, Lyrica (pregabalin), DS-5565, pregabalin, Fentanyl, Lidoderm, and others.

• Postherpetic Neuralgia Pipeline Segmentation- Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Postherpetic Neuralgia Market Drivers and Postherpetic Neuralgia Market Barriers, click here @ Postherpetic Neuralgia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Postherpetic Neuralgia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Postherpetic Neuralgia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. HSK16149: Haisco Pharmaceutical Group
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LX9211: Lexicon Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. AAT 730: Oxford Technologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Postherpetic Neuralgia Key Companies
21. Postherpetic Neuralgia Key Products
22. Postherpetic Neuralgia- Unmet Needs
23. Postherpetic Neuralgia- Market Drivers and Barriers
24. Postherpetic Neuralgia- Future Perspectives and Conclusion
25. Postherpetic Neuralgia Analyst Views
26. Postherpetic Neuralgia Key Companies
27. Appendix

Got Queries? Find out the related information on Postherpetic Neuralgia Mergers and acquisitions, Postherpetic Neuralgia Licensing Activities @ Postherpetic Neuralgia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.